Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?

Vikas Garg; Amit M Oza

doi:10.1158/1078-0432.CCR-24-3905

Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?

Clin Cancer Res. 2025 Jun 3;31(11):2073-2076. doi: 10.1158/1078-0432.CCR-24-3905.

Authors

Vikas Garg¹, Amit M Oza^{1

2}

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
² Department of Medicine, University of Toronto, Toronto, Canada.

PMID: 40117127
DOI: 10.1158/1078-0432.CCR-24-3905

Abstract

Endocrine therapy (ET) has been underexplored in endometrial cancer. Emerging data suggest that combining ET with cyclin-dependent kinase 4/6 inhibitors improves outcomes in endometrial cancer. This commentary complements a recent CCR article and reviews the opportunities to improve precision ET and the potential to overcome resistance mechanisms associated with ET failure. See related article by Green et al., p. 2088.

MeSH terms

Antineoplastic Agents, Hormonal* / pharmacology
Antineoplastic Agents, Hormonal* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
Drug Resistance, Neoplasm / drug effects
Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Endometrial Neoplasms* / metabolism
Endometrial Neoplasms* / pathology
Female
Humans
Precision Medicine* / methods

Substances

Antineoplastic Agents, Hormonal
Cyclin-Dependent Kinase 4